• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Sanofi Genzyme - Articles and news items

prostate cancer

Scottish Medicines Consortium approves Sanofi prostate cancer drug

Industry news / 14 December 2016 / Niamh Louise Marriott, Digital Editor

Prostate cancer can become resistant to hormone therapy and continue to grow despite treatment. Jevtana (cabazitaxel) is the only remaining chemotherapy…

application

EMA to review Sanofi and Regeneron’s dermatitis drug application

Industry news / 13 December 2016 / Niamh Louise Marriott, Digital Editor

The European Medicines Agency (EMA) has accepted for review the marketing authorisation application for Sanofi and Regeneron’s Dupixent (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. The investigational biologic therapy Dupixent inhibits signaling of IL-4 and IL-13, two key cytokines required for the type 2 (including Th2) […]

study

Sanofi and Regeneron’s rheumatoid arthritis drug shows superior results

Industry news / 21 November 2016 / Niamh Louise Marriott, Digital Content Producer

Sanofi and Regeneron presented results of a Phase 3 study demonstrating the superiority of investigational sarilumab monotherapy versus adalimumab…

UK Phase 2/3 acid sphingomyelinase deficiency trial begins

Industry news / 3 November 2016 / Niamh Louise Marriott, Digital Content Producer

Olipudase alfa is an enzyme replacement therapy being studied as a treatment of non-neurological manifestations of acid sphingomyelinase deficiency (ASMD)…

NICE recommends Jevtana for advanced prostate cancer

Industry news / 25 May 2016 / Victoria White, Digital Content Producer

Jevtana has been recommended in combination with other drugs as a treatment option for metastatic hormone-relapsed prostate cancer in England…

Sanofi makes huge investment in biologics

Sanofi makes huge investment in the future of biologics

Industry news / 19 April 2016 / Mandy Parrett, Editorial Assistant

Sanofi has announced plans to invest €300 million to expand its manufacturing and commercial capabilities at its site in Geel, Belgium.

 

Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringWATCH NOW
+ +